OGI vs. CPH, CRDL, HLS, ACB, GUD, DR, VHI, QIPT, MDNA, and FRX
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Cipher Pharmaceuticals (CPH), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Aurora Cannabis (ACB), Knight Therapeutics (GUD), Medical Facilities (DR), Vitalhub (VHI), Quipt Home Medical (QIPT), Medicenna Therapeutics (MDNA), and Fennec Pharmaceuticals (FRX). These companies are all part of the "medical" sector.
Cipher Pharmaceuticals (TSE:CPH) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.
Cipher Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Cipher Pharmaceuticals has a net margin of 102.43% compared to Cipher Pharmaceuticals' net margin of -153.80%. Organigram's return on equity of 29.70% beat Cipher Pharmaceuticals' return on equity.
Cipher Pharmaceuticals has higher earnings, but lower revenue than Organigram. Organigram is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Organigram had 16 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 20 mentions for Organigram and 4 mentions for Cipher Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 0.12 beat Organigram's score of -0.33 indicating that Organigram is being referred to more favorably in the news media.
Cipher Pharmaceuticals received 131 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 62.46% of users gave Cipher Pharmaceuticals an outperform vote while only 44.34% of users gave Organigram an outperform vote.
Cipher Pharmaceuticals presently has a consensus target price of C$8.75, suggesting a potential upside of 0.69%. Organigram has a consensus target price of C$3.76, suggesting a potential upside of 38.68%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Organigram is more favorable than Cipher Pharmaceuticals.
1.1% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 9.0% of Organigram shares are held by institutional investors. 44.5% of Cipher Pharmaceuticals shares are held by company insiders. Comparatively, 27.3% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Cipher Pharmaceuticals beats Organigram on 10 of the 18 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
